Ophthotech Corporation Company Profile (NASDAQ:OPHT)

About Ophthotech Corporation (NASDAQ:OPHT)

Ophthotech Corporation logoOphthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OPHT
  • CUSIP: N/A
  • Web: www.ophthotech.com
Capitalization:
  • Market Cap: $88.06 million
  • Outstanding Shares: 35,943,000
Average Prices:
  • 50 Day Moving Avg: $2.66
  • 200 Day Moving Avg: $2.69
  • 52 Week Range: $2.24 - $41.43
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.23
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.31 million
  • Price / Sales: 8.40
  • Book Value: ($4.14) per share
  • Price / Book: -0.58
Profitability:
  • EBITDA: ($181,990,000.00)
  • Net Margins: -1,866.58%
  • Return on Assets: -70.63%
Debt:
  • Current Ratio: 7.81%
  • Quick Ratio: 7.81%
Misc:
  • Average Volume: 518,642 shs.
  • Beta: 1.46
  • Short Ratio: 5.92
 

Frequently Asked Questions for Ophthotech Corporation (NASDAQ:OPHT)

What is Ophthotech Corporation's stock symbol?

Ophthotech Corporation trades on the NASDAQ under the ticker symbol "OPHT."

How were Ophthotech Corporation's earnings last quarter?

Ophthotech Corporation (NASDAQ:OPHT) announced its earnings results on Wednesday, July, 26th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.45. The business had revenue of $1.66 million for the quarter, compared to analysts' expectations of $1.38 million. The business's revenue was down 94.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) earnings per share. View Ophthotech Corporation's Earnings History.

When will Ophthotech Corporation make its next earnings announcement?

Ophthotech Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Ophthotech Corporation.

Where is Ophthotech Corporation's stock going? Where will Ophthotech Corporation's stock price be in 2017?

12 analysts have issued 12-month price targets for Ophthotech Corporation's shares. Their forecasts range from $4.00 to $92.00. On average, they expect Ophthotech Corporation's stock price to reach $47.33 in the next year. View Analyst Ratings for Ophthotech Corporation.

Who are some of Ophthotech Corporation's key competitors?

Who are Ophthotech Corporation's key executives?

Ophthotech Corporation's management team includes the folowing people:

  • David R. Guyer M.D., Executive Chairman of the Board
  • Glenn P. Sblendorio, President, Chief Executive Officer
  • David Carroll, Chief Financial Officer, Senior Vice President, Treasurer
  • Keith Westby, Chief Operating Officer, Senior Vice President
  • Barbara A. Wood Esq., Senior Vice President, General Counsel, Secretary
  • David E. Redlick, Lead Independent Director
  • Axel Bolte, Independent Director
  • Thomas Dyrberg M.D., Independent Director
  • Michael Jay Ross Ph. D., Independent Director

How do I buy Ophthotech Corporation stock?

Shares of Ophthotech Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ophthotech Corporation's stock price today?

One share of Ophthotech Corporation stock can currently be purchased for approximately $2.41.


MarketBeat Community Rating for Ophthotech Corporation (NASDAQ OPHT)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Ophthotech Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ophthotech Corporation (NASDAQ:OPHT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $47.33 (1,864.04% upside)
Consensus Price Target History for Ophthotech Corporation (NASDAQ:OPHT)
Price Target History for Ophthotech Corporation (NASDAQ:OPHT)
Analysts' Ratings History for Ophthotech Corporation (NASDAQ:OPHT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Stifel NicolausReiterated RatingHold$4.00LowView Rating Details
12/13/2016GabelliDowngradeBuy -> HoldN/AView Rating Details
12/13/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
12/12/2016Goldman Sachs Group IncUpgradeSell -> NeutralN/AView Rating Details
12/12/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/12/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
12/12/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
12/12/2016Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
12/12/2016Barclays PLCDowngradeOverweight -> Equal WeightN/AView Rating Details
12/12/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$11.00N/AView Rating Details
12/12/2016SunTrust Banks, Inc.DowngradeBuy -> HoldN/AView Rating Details
12/12/2016Chardan CapitalDowngradeBuy -> Neutral$15.00N/AView Rating Details
11/19/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$95.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Ophthotech Corporation (NASDAQ:OPHT)
Earnings by Quarter for Ophthotech Corporation (NASDAQ:OPHT)
Earnings History by Quarter for Ophthotech Corporation (NASDAQ OPHT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.84)N/AView Earnings Details
7/26/2017Q2 2017($1.07)($0.62)$1.38 million$1.66 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.31)($1.20)$1.94 million$1.66 millionViewListenView Earnings Details
11/8/2016Q316($1.64)($1.71)$6.20 million$1.67 millionViewListenView Earnings Details
8/3/2016Q216($1.05)($0.85)$18.64 million$28.20 millionViewListenView Earnings Details
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ophthotech Corporation (NASDAQ:OPHT)
2017 EPS Consensus Estimate: ($1.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.45)($1.45)($1.45)
Q2 20172($1.19)($1.14)($1.17)
Q3 20172($1.04)$4.23$1.60
Q4 20172($0.79)($0.65)($0.72)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ophthotech Corporation (NASDAQ:OPHT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ophthotech Corporation (NASDAQ:OPHT)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 61.40%
Insider Trades by Quarter for Ophthotech Corporation (NASDAQ:OPHT)
Institutional Ownership by Quarter for Ophthotech Corporation (NASDAQ:OPHT)
Insider Trades by Quarter for Ophthotech Corporation (NASDAQ:OPHT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Barbara A WoodSVPSell5,119$2.58$13,207.02View SEC Filing  
7/5/2017David Francis CarrollCFOSell3,284$2.58$8,472.72View SEC Filing  
7/5/2017David R GuyerChairmanSell17,678$2.58$45,609.24View SEC Filing  
7/5/2017Glenn SblendorioCEOSell7,828$2.58$20,196.24View SEC Filing  
6/13/2017David E RedlickDirectorSell700$2.52$1,764.00View SEC Filing  
4/3/2017Glenn SblendorioCFOSell7,388$3.56$26,301.28View SEC Filing  
1/5/2017David R GuyerCEOSell3,785$4.96$18,773.60View SEC Filing  
1/5/2017Henric Bjorn BjarkeSVPSell316$4.96$1,567.36View SEC Filing  
1/5/2017Samir Chandrakant PatelPresidentSell3,844$4.96$19,066.24View SEC Filing  
1/3/2017Barbara A WoodSVPSell675$4.90$3,307.50View SEC Filing  
1/3/2017David R GuyerCEOSell3,484$4.90$17,071.60View SEC Filing  
1/3/2017Samir Chandrakant PatelPresidentSell2,999$4.90$14,695.10View SEC Filing  
12/23/2016Barbara A. WoodSVPSell746$4.92$3,670.32View SEC Filing  
12/22/2016Glenn SblendorioCFOSell1,079$4.85$5,233.15View SEC Filing  
12/15/2016A/S NovoMajor ShareholderSell3,610,487$4.87$17,583,071.69View SEC Filing  
11/1/2016David R GuyerCEOSell22,060$35.61$785,556.60View SEC Filing  
10/3/2016David R GuyerCEOSell22,060$44.37$978,802.20View SEC Filing  
9/29/2016Samir Chandrakant PatelPresidentSell20,000$55.17$1,103,400.00View SEC Filing  
8/29/2016Samir Chandrakant PatelPresidentSell20,000$52.80$1,056,000.00View SEC Filing  
8/1/2016David R GuyerCEOSell24,060$64.47$1,551,148.20View SEC Filing  
7/29/2016Samir Chandrakant PatelPresidentSell20,000$64.21$1,284,200.00View SEC Filing  
7/1/2016David R GuyerCEOSell24,060$52.12$1,254,007.20View SEC Filing  
6/30/2016Samir Chandrakant PatelPresidentSell41,846$51.23$2,143,770.58View SEC Filing  
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.00View SEC Filing  
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.20View SEC Filing  
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.60View SEC Filing  
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00View SEC Filing  
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.00View SEC Filing  
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.80View SEC Filing  
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00View SEC Filing  
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.60View SEC Filing  
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00View SEC Filing  
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.80View SEC Filing  
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00View SEC Filing  
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00View SEC Filing  
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.74View SEC Filing  
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.00View SEC Filing  
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00View SEC Filing  
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.24View SEC Filing  
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00View SEC Filing  
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24View SEC Filing  
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.00View SEC Filing  
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.18View SEC Filing  
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05View SEC Filing  
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.00View SEC Filing  
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85View SEC Filing  
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05View SEC Filing  
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.58View SEC Filing  
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10View SEC Filing  
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.16View SEC Filing  
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25View SEC Filing  
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.00View SEC Filing  
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  
5/1/2014David GuyerCEOSell10,665$33.71$359,517.15View SEC Filing  
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55View SEC Filing  
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  
3/24/2014David GuyerCEOSell12,027$34.53$415,292.31View SEC Filing  
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04View SEC Filing  
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04View SEC Filing  
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ophthotech Corporation (NASDAQ:OPHT)
Latest Headlines for Ophthotech Corporation (NASDAQ:OPHT)
Source:
DateHeadline
americanbankingnews.com logoOphthotech Corporation (OPHT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 12 at 6:56 PM
finance.yahoo.com logoHow Should You Think About Ophthotech Corporation’s (OPHT) Risks?
finance.yahoo.com - October 9 at 8:47 PM
americanbankingnews.com logo$180.65 Million in Sales Expected for Ophthotech Corporation (OPHT) This Quarter
www.americanbankingnews.com - October 4 at 1:24 AM
americanbankingnews.com logoOphthotech Corp (OPHT) Expected to Post Earnings of $4.31 Per Share
www.americanbankingnews.com - October 3 at 12:28 AM
nasdaq.com logoHow is the Age-Related Macular Degeneration Space Faring Now? - Nasdaq
www.nasdaq.com - September 22 at 7:32 AM
finance.yahoo.com logoHow is the Age-Related Macular Degeneration Space Faring Now?
finance.yahoo.com - September 22 at 7:32 AM
americanbankingnews.com logoOphthotech Corporation's (OPHT) Hold Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - September 21 at 1:52 PM
streetinsider.com logoOphthotech Corp (OPHT) Reports Update on Zimura Complement Programs for Treatment of Eye Diseases
www.streetinsider.com - September 20 at 7:19 AM
reuters.com logoBRIEF-Ophthotech gives update on programs for treatment of eye diseases
www.reuters.com - September 20 at 7:19 AM
finance.yahoo.com logoOphthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases
finance.yahoo.com - September 20 at 7:19 AM
americanbankingnews.com logoOphthotech Corporation (OPHT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 17 at 4:46 PM
americanbankingnews.com logoAnalysts Issue Forecasts for Ophthotech Corporation's FY2020 Earnings (OPHT)
www.americanbankingnews.com - September 13 at 4:02 PM
nasdaq.com logoRoche's Ophthalmology Drug Fails to Meet Primary Endpoint - Nasdaq - Nasdaq
www.nasdaq.com - September 12 at 8:15 AM
finance.yahoo.com logoRoche's Ophthalmology Drug Fails to Meet Primary Endpoint
finance.yahoo.com - September 12 at 8:15 AM
marketwatch.com logoRoche shares decline 1.6% on news that late-stage study missed primary endpoint - MarketWatch
www.marketwatch.com - September 9 at 7:02 AM
seekingalpha.com logoRoche lampalizumab flop weighs on Ophthotech, down 10 ... - Seeking Alpha
seekingalpha.com - September 9 at 7:02 AM
finance.yahoo.com logoRoche shares decline 1.6% on news that late-stage study missed primary endpoint
finance.yahoo.com - September 9 at 7:02 AM
nasdaq.com logoWhy Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - August 31 at 8:23 AM
finance.yahoo.com logoWhy Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report?
finance.yahoo.com - August 30 at 7:39 AM
americanbankingnews.com logoOphthotech Corporation (OPHT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 23 at 6:46 PM
seekingalpha.com logoOphthotech: 3 Strikes And It's Out? - Seeking Alpha
seekingalpha.com - August 22 at 2:31 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: August 16, 2017
seekingalpha.com - August 18 at 6:51 AM
nasdaq.com logoOphthotech's Fovista Combo Regimen Disappoints in Phase III - Nasdaq
www.nasdaq.com - August 17 at 6:34 AM
finance.yahoo.com logoOphthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration
finance.yahoo.com - August 16 at 6:31 AM
streetinsider.com logoOphthotech Corp (OPHT) Phase 3 Trial of Fovista in Wet AMD Didn't Meet Primary Endpoint - StreetInsider.com
www.streetinsider.com - August 15 at 5:50 AM
americanbankingnews.com logo$4.31 EPS Expected for Ophthotech Corporation (NASDAQ:OPHT) This Quarter
www.americanbankingnews.com - August 8 at 10:28 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for Ophthotech Corporation's FY2017 Earnings (NASDAQ:OPHT)
www.americanbankingnews.com - July 31 at 8:15 AM
americanbankingnews.com logoQ3 2017 Earnings Forecast for Ophthotech Corporation Issued By Leerink Swann (NASDAQ:OPHT)
www.americanbankingnews.com - July 31 at 7:41 AM
americanbankingnews.com logoOphthotech Corporation (NASDAQ:OPHT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 29 at 4:43 PM
nasdaq.com logoOphthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura - Nasdaq
www.nasdaq.com - July 29 at 6:04 AM
americanbankingnews.com logoOphthotech Corporation (NASDAQ:OPHT) to Post Q4 2017 Earnings of ($0.65) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - July 28 at 3:33 PM
reuters.com logoBRIEF-Ophthotech reports second quarter 2017 financial and operating results
www.reuters.com - July 27 at 6:07 AM
streetinsider.com logoOphthotech Corp (OPHT) Posts Smaller-than-Expected Q2 Loss
www.streetinsider.com - July 27 at 6:07 AM
seekingalpha.com logoOphthotech Corporation 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - July 27 at 6:07 AM
finance.yahoo.com logoOphthotech Expands Focus with Development for Ophthalmic Orphan Diseases
finance.yahoo.com - July 27 at 6:07 AM
finance.yahoo.com logoOphthotech Reports Second Quarter 2017 Financial and Operating Results
finance.yahoo.com - July 27 at 6:07 AM
finance.yahoo.com logoOphthotech reports 2Q loss
finance.yahoo.com - July 27 at 6:07 AM
finance.yahoo.com logoEdited Transcript of OPHT earnings conference call or presentation 26-Jul-17 12:00pm GMT
finance.yahoo.com - July 27 at 6:07 AM
americanbankingnews.com logoOphthotech Corporation (OPHT) Issues Earnings Results
www.americanbankingnews.com - July 26 at 11:44 AM
businesswire.com logoOphthotech Corporation to Report Second Quarter 2017 Financial ... - Business Wire (press release)
www.businesswire.com - July 22 at 7:20 AM
finance.yahoo.com logoOphthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017
finance.yahoo.com - July 22 at 7:20 AM
americanbankingnews.com logoOphthotech Corporation (OPHT) Expected to Post Quarterly Sales of $1.44 Million
www.americanbankingnews.com - July 21 at 9:08 PM
americanbankingnews.com logo Analysts Expect Ophthotech Corp (OPHT) to Post -$1.09 Earnings Per Share
www.americanbankingnews.com - July 19 at 8:53 AM
businesswire.com logoGlobal $8.91 Billion Aptamers (Nucleic Acid & Peptide) Market 2014-2017 - Forecasts to 2025 - Research and Markets
www.businesswire.com - July 14 at 7:12 AM
americanbankingnews.com logoOphthotech Corporation (NASDAQ:OPHT) SVP Sells $13,207.02 in Stock
www.americanbankingnews.com - July 5 at 8:32 PM
americanbankingnews.com logoOphthotech Corporation (OPHT) CEO Sells $20,196.24 in Stock
www.americanbankingnews.com - July 5 at 8:32 PM
americanbankingnews.com logoInsider Selling: Ophthotech Corporation (NASDAQ:OPHT) Chairman Sells 17,678 Shares of Stock
www.americanbankingnews.com - July 5 at 8:08 PM
americanbankingnews.com logoOphthotech Corporation (OPHT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 4 at 5:23 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Ophthotech, Pacific Biosciences of California, PTC Therapeutics, and Portola ... - PR Newswire (press release)
www.prnewswire.com - May 24 at 10:15 AM
reuters.com logoBRIEF-David Shaw reports a 5 pct passive stake in Ophthotech Corp as of May 11 ...
www.reuters.com - May 22 at 6:15 PM

Social

Chart

Ophthotech Corporation (OPHT) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.